Clinical Trial Update: Voriconazole to Prevent Systemic Fungal Infections in Children [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates voriconazole for the prevention of systemic fungal infections in pediatric patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Candidiasis
• Fungal Diseases
• Mycoses

Drugs mentioned

• VFEND (Voriconazole)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Aspergillosis, Candidiasis | Phase 1 | Status: COMPLETED